SCHEMBL1735347

SCHEMBL1735347

NC(N)=NCCCC(=O)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.48
NFKB1 P19838 2/20 0.48
GLA P06280 1/20 0.48
TSHR P16473 1/20 0.48
APEX1 P27695 1/20 0.48
CYP2C19 P33261 1/20 0.48
NOS2 P35228 1/20 0.48
ALOX15 P16050 1/20 0.44
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
CPN1 P15169 1/20 0.44
CPB2 Q96IY4 1/20 0.44
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM1 P11229 1/20 0.43
DHPS P49366 1/20 0.43
BLM P54132 1/20 0.42
PMP22 Q01453 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1743686 0.81 CYP1A2 (0.52) CYP1A2NFKB1GLATSHRAPEX1
Tiformin SCHEMBL1736430 0.80 CYP1A2 (0.52) CYP1A2NFKB1GLATSHRAPEX1
SCHEMBL26921963 0.78 NOS2 (0.42) CYP1A2NFKB1GLATSHRAPEX1
SCHEMBL4670166 0.74 CHRM2 (0.53) CYP1A2NFKB1GLATSHRAPEX1
Arginine SCHEMBL29377479 0.74 NOS2 (0.73) CYP1A2NFKB1GLATSHRAPEX1
Arginine SCHEMBL28029598 0.74 NOS2 (0.73) CYP1A2NFKB1GLATSHRAPEX1
SCHEMBL31147718 0.73 CHRM2 (0.57) CYP1A2NFKB1GLATSHRAPEX1
SCHEMBL5541512 0.73 CHRM2 (0.56) CYP1A2NFKB1TSHRALOX15MAOA
SCHEMBL6267121 0.72 OR51E2 (0.48) CYP1A2GLATSHRCYP2C19ALOX15
SCHEMBL21600751 0.72 OR51E2 (0.48) CYP1A2NFKB1TSHRCYP2C19ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250076302-A1 DETECTING THE PRESENCE OF URINARY STONE DISEASE USING A PLURALITY OF URINARY METABOLITES THE CLEVELAND CLINIC FOUNDATION 2025-03-06 US claimed
CN-116926580-A Method for producing amino acid by using nitrogen oxide waste gas and waste water 中山大学 2023-10-24 CN claimed
CN-116926619-A Amino acid synthesis method 中山大学 2023-10-24 CN claimed
EP-4022089-A1 METHODS FOR IDENTIFYING A COMPANION ANIMAL AT RISK OF CALCIUM OXALATE STONE FORMATION AND TREATMENTS AND COMPOSITIONS FOR REDUCING THE RISK Hill's Pet Nutrition, Inc. (US) 2022-07-06 EP claimed
US-20260091067-A1 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES MARVELBIOME INC (US) 2026-04-02 US disclosed
US-20250388910-A1 METHODS FOR ENHANCING MICROBIAL PRODUCTION OF SPECIFIC LENGTH FATTY ALCOHOLS IN THE PRESENCE OF METHANOL AGAIN BIO APS (DK) 2025-12-25 US disclosed
US-12398396-B2 Methods for enhancing microbial production of specific length fatty alcohols in the presence of methanol GENOMATICA, INC. (US) 2025-08-26 US disclosed
EP-4587116-A2 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES MarvelBiome, Inc. (US) 2025-07-23 EP disclosed
US-20250076302-A1 DETECTING THE PRESENCE OF URINARY STONE DISEASE USING A PLURALITY OF URINARY METABOLITES THE CLEVELAND CLINIC FOUNDATION 2025-03-06 US disclosed
US-20250076302-A1 DETECTING THE PRESENCE OF URINARY STONE DISEASE USING A PLURALITY OF URINARY METABOLITES THE CLEVELAND CLINIC FOUNDATION 2025-03-06 US disclosed
US-20250043352-A1 Methods for Identifying a Companion Animal at Risk of Calcium Oxalate Stone Formation and Treatments and Compositions for Reducing the Risk HILL'S PET NUTRITION, INC. (US) 2025-02-06 US disclosed
EP-3074504-B1 METHODS FOR ENHANCING MICROBIAL PRODUCTION OF SPECIFIC LENGTH FATTY ALCOHOLS IN THE PRESENCE OF METHANOL GENOMATICA INC (US) 2024-12-25 EP disclosed
CN-103038195-B Device and method for solubilizing, separating, removing and reacting carboxylic acids in oils, fats, aqueous or organic solutions by micro-or nanoemulsification ULRICH DIETZ (DE) 2016-04-13 CN disclosed
EP-2585420-B1 METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO- OR NANOEMULSIFICATION DIETZ ULRICH (DE) 2016-04-06 EP disclosed
US-9127233-B2 Device and method for solubilizing, separating, removing and reacting carboxylic acids in oils, fats, aqueous or organic solutions by means of micro-or nanoemulsification Dietz, Ulrich (DE) 2015-09-08 US disclosed
EP-2585420-A2 DEVICE AND METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO- OR NANOEMULSIFICATION Dietz, Ulrich (DE) 2013-05-01 EP disclosed
US-20130090488-A1 DEVICE AND METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO-OR NANOEMULSIFICATION DIETZ ULRICH (DE) 2013-04-11 US disclosed
CN-103038195-A Device and method for solubilizing, separating, removing and reacting carboxylic acids in oils, fats, aqueous or organic solutions by micro-or nanoemulsification DIETZ ULRICH 2013-04-10 CN disclosed
WO-2011160857-A2 DEVICE AND METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO- OR NANOEMULSIFICATION DIETZ ULRICH (DE) 2011-12-29 WO disclosed
EP-2399885-A1 Device and method for solubilizing, separating, removing and reacting carboxylic acids in aqueous or organic solutions by means of micro- or nanoemulsification Dietz, Ulrich (DE) 2011-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388910-A1 METHODS FOR ENHANCING MICROBIAL PRODUCTION OF SPECIFIC LENGTH FATTY ALCOHOLS IN THE PRESENCE OF METHANOL ADH5, ADH1C, ADH1A CYP1A2 740/4885NFKB1 3449/4885GLA 1079/4885
US-20260091067-A1 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES IAPP, GPR119, FAHD1 CYP1A2 862/4885NFKB1 4585/4885GLA 1913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.